Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study
Background Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in COVID-19 infection. The study was aimed to explore the association between ivermectin prophylaxis and development of COVID-19 infection among healthcare workers.Methods A hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020. Profession, gender, age and date of diagnosis were matched for 186 case-control pairs. Cases and controls were healthcare workers who tested positive and negative, respectively, for COVID-19 by RT-PCR. Exposure was defined as the intake of ivermectin and/or hydroxychloroquine and/or vitamin-C and/or other prophylaxis for COVID-19. Data collection and entry was done in Epicollect5, and analysis was performed using STATA version 13. Conditional logistic regression models were used to describe the associated factors for COVID-19 infection.Results Ivermectin prophylaxis was taken by 77 controls and 38 cases. Two-dose ivermectin prophylaxis (0.27, 95% CI, 0.15-0.51) was associated with 73% reduction of COVID-19 infection among healthcare workers for the following one month, those who were involved in physical activity (3.06 95% CI, 1.18-7.93) for more than an hour/day were more likely to contract COVID-19 infection. Type of household, COVID duty, single-dose ivermectin prophylaxis, vitamin-C prophylaxis and hydroxychloroquine prophylaxis were not associated with COVID-19 infection.Conclusion Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated 73% reduction of COVID-19 infection among healthcare workers for the following one-month. Further research is required before its large scale use..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
bioRxiv.org - (2020) vom: 05. Nov. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Behera, Priyamadhaba [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2020.10.29.20222661 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019261160 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019261160 | ||
| 003 | DE-627 | ||
| 005 | 20230429101227.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201106s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.10.29.20222661 |2 doi | |
| 035 | |a (DE-627)XBI019261160 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.10.29.20222661 | ||
| 035 | |a (biorXiv)10.1101/2020.10.29.20222661 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Behera, Priyamadhaba |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in COVID-19 infection. The study was aimed to explore the association between ivermectin prophylaxis and development of COVID-19 infection among healthcare workers.Methods A hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020. Profession, gender, age and date of diagnosis were matched for 186 case-control pairs. Cases and controls were healthcare workers who tested positive and negative, respectively, for COVID-19 by RT-PCR. Exposure was defined as the intake of ivermectin and/or hydroxychloroquine and/or vitamin-C and/or other prophylaxis for COVID-19. Data collection and entry was done in Epicollect5, and analysis was performed using STATA version 13. Conditional logistic regression models were used to describe the associated factors for COVID-19 infection.Results Ivermectin prophylaxis was taken by 77 controls and 38 cases. Two-dose ivermectin prophylaxis (0.27, 95% CI, 0.15-0.51) was associated with 73% reduction of COVID-19 infection among healthcare workers for the following one month, those who were involved in physical activity (3.06 95% CI, 1.18-7.93) for more than an hour/day were more likely to contract COVID-19 infection. Type of household, COVID duty, single-dose ivermectin prophylaxis, vitamin-C prophylaxis and hydroxychloroquine prophylaxis were not associated with COVID-19 infection.Conclusion Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated 73% reduction of COVID-19 infection among healthcare workers for the following one-month. Further research is required before its large scale use. | ||
| 700 | 1 | |a Patro, Binod Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Arvind Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Chandanshive, Pradnya Dilip |e verfasserin |4 aut | |
| 700 | 1 | |a S.R., Ravi Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Pradhan, Somen Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Pentapati, Siva Santosh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Batmanabane, Gitanjali |e verfasserin |4 aut | |
| 700 | 1 | |a Padhy, Biswa Mohan |e verfasserin |4 aut | |
| 700 | 1 | |a Bal, Shakti |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sudipta Ranjan |e verfasserin |4 aut | |
| 700 | 1 | |a Mohanty, Rashmi Ranjan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 05. Nov. |
| 773 | 1 | 8 | |g year:2020 |g day:05 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.10.29.20222661 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 05 |c 11 | ||
| 953 | |2 045F |a 570 | ||